Sirnaomics Ltd

Sirnaomics has a market capitalization of USD 663.8 million, with a market price of USD 6.05 per share. The company has 109.7 million shares outstanding, with no dilution from potential share issuance as of the latest data. The liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

The company reported a loss per share of USD -1.16 in the latest period, with no revenue recorded. This indicates a lack of commercialization of its products to date, and the company is likely in the research and development phase. The absence of revenue and the negative EPS suggest that the company is not yet generating returns for shareholders and is likely relying on capital raising to fund operations.

There is no disclosed segment or geographic breakdown of revenue, as the company has not yet generated any revenue. This lack of diversification in revenue sources increases the risk for investors, as the company's future success is entirely dependent on the development and commercialization of its pipeline products.

The company's growth trajectory is uncertain, as there is no historical revenue data to assess growth trends. The absence of revenue and the negative EPS suggest that the company is not yet in a growth phase and is likely in the early stages of development. The company's future growth will depend on the success of its clinical trials and the ability to secure regulatory approvals for its products.

The risk assessment indicates a low dilution risk, but the liquidity risk could not be assessed due to the lack of balance-sheet data. The company may be at risk of dilution if it needs to raise additional capital to fund its operations, which could negatively impact existing shareholders. The absence of going-concern language in the source documents raises concerns about the company's ability to continue as a going concern.

There are no recent events or filings disclosed in the source documents that would indicate significant changes in the company's operations or financial position. The company's financial performance and risk profile remain largely unchanged based on the available data.

Revenue $0.00, −100,0% YoY; Operating income +72,0% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +72,0% YoY
• ▍Net income +72,0% YoY
• ▍Free cash flow +71,4% YoY

Revenue $1.8M; Operating income +41,4% YoY.

• ▍Revenue $1.8M
• ▍Operating income +41,4% YoY
• ▍Net income +34,7% YoY
• ▍Free cash flow +44,4% YoY
• ▍Net margin -2889.9%